[Novel Therapeutic Strategy for Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer]
Nobuhiko Kanaya1, Shinji Kuroda, Tetsushi Kubota
1Dept. of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
Abstract:
Trastuzumab(Tmab), a humanized monoclonal antibody that selectively targets human epidermal growth factor receptor 2(HER2), is currently used in the clinical setting for the treatment of both breast and gastric cancer. While Tmab has shown improvements in patient prognoses, acquired resistance to this agent remains an issue. While some novel HER2-targeted agents have been approved for clinical use in breast cancer, no such agent has shown treatment efficacy for gastric malignancies with Tmab-resistance. Nanotechnology, which has progressed rapidly, has been applied to medical fields in recent years. Gold nanoparticles, which are characterized by their in vivo stability and ease of surface modification, have been reported to show efficacy as the carriers of therapeutic agents, such as drugs, antibodies, peptides, and nucleic acids. In this work, we developed Tmab-conjugated gold nanoparticles and demonstrate their efficacy for the treatment of HER2-positive, Tmabresistant gastric cancer cell lines. Our findings demonstrate that Tmab-conjugated gold nanoparticles have the potential to be a novelHER2 -targeted therapeutic agent.
Insights
Trastuzumab-conjugated gold nanoparticles show promise for treating HER2-positive gastric cancer resistant to Trastuzumab. This nanotechnology approach offers a potential new therapeutic strategy for patients with limited options.
Area of Science:
- Oncology
- Nanotechnology
- Immunotherapy
Background:
- Trastuzumab (Tmab) is a humanized monoclonal antibody targeting HER2, used for breast and gastric cancers.
- Acquired resistance to Trastuzumab is a significant clinical challenge, particularly in gastric cancer.
- Existing HER2-targeted therapies show limited efficacy in Trastuzumab-resistant gastric malignancies.
Purpose of the Study:
- To develop and evaluate Trastuzumab-conjugated gold nanoparticles (Tmab-AuNPs) as a novel therapeutic agent.
- To assess the efficacy of Tmab-AuNPs against Trastuzumab-resistant HER2-positive gastric cancer cell lines.
Main Methods:
- Conjugation of Trastuzumab to gold nanoparticles.
- In vitro testing of Tmab-AuNPs on HER2-positive, Trastuzumab-resistant gastric cancer cell lines.
Main Results:
- Tmab-conjugated gold nanoparticles demonstrated efficacy in treating Trastuzumab-resistant HER2-positive gastric cancer cells.
- Gold nanoparticles serve as effective carriers for therapeutic antibodies like Trastuzumab.
Conclusions:
- Tmab-conjugated gold nanoparticles represent a potential novel therapeutic strategy for Trastuzumab-resistant HER2-positive gastric cancer.
- Nanotechnology offers a promising platform for overcoming drug resistance in cancer therapy.
More Related Videos
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...